| ALK fusion-positive (N = 22) . | ALK-WT (N = 8869) . | ||
|---|---|---|---|
| Matched (N = 88) . | Non-matched (N = 8,781) . | ||
| Sex, n (%) | |||
| Female | 13 (59.1) | 45 (51.1) | 4163 (47.4) |
| Male | 9 (40.9) | 43 (48.9) | 4618 (52.6) |
| Mean age, years (SD)a | 62.6 (15.7) | 62.2 (11.9) | 62.7 (12.2) |
| Race, n (%) | |||
| Asian | 0 | 0 | 203 (2.3) |
| Black/African American | 2 (9.1) | 4 (4.5) | 816 (9.3) |
| Hispanic/Latino | 0 | 0 | 16 (0.2) |
| White | 18 (81.8) | 80 (90.9) | 5623 (64.0) |
| Other/missing | 2 (9.1) | 4 (4.5) | 2123 (24.2) |
| ECOG PS, n (%) | |||
| 0 | 5 (22.7) | 26 (29.5) | 2146 (24.4) |
| 1 | 9 (40.9) | 28 (31.8) | 2816 (32.1) |
| 2 | 0 | 0 | 822 (9.4) |
| ≥3 | 1 (4.5) | 4 (4.5) | 237 (2.7) |
| Missing | 7 (31.8) | 30 (34.1) | 2760 (31.4) |
| Number of prior lines of treatment, n (%) | |||
| 0 | 3 (13.6) | 12 (13.6) | 1247 (14.2) |
| 1 | 7 (31.8) | 32 (36.4) | 3363 (38.3) |
| 2 | 1 (4.5) | 4 (4.5) | 1120 (12.8) |
| ≥3 | 2 (9.1) | 8 (9.1) | 1208 (13.7) |
| Missing | 9 (40.9) | 32 (36.4) | 1843 (21.0) |
| Year of CGP report, n (%) | |||
| <2019 | 4 (18.2) | 16 (18.2) | 3213 (36.6) |
| 2019 | 2 (9.1) | 8 (9.1) | 1441 (16.4) |
| 2020 | 6 (27.3) | 25 (28.4) | 1381 (15.7) |
| 2021 | 6 (27.3) | 25 (28.4) | 1303 (14.8) |
| 2022 | 3 (13.6) | 10 (11.4) | 1190 (13.6) |
| 2023 | 1 (4.5) | 4 (4.5) | 253 (2.9) |
| Mean follow-up time from CGP report, months (IQR) | 5.0 (16.8) | 10.6 (16.9) | 9.0 (16.1) |
| Mean time from initial diagnosisb to CGP report date, months (IQR) | 2.1 (5.6) | 2.7 (9.8) | 3.9(17.8) |
| ALK fusion-positive (N = 22) . | ALK-WT (N = 8869) . | ||
|---|---|---|---|
| Matched (N = 88) . | Non-matched (N = 8,781) . | ||
| Sex, n (%) | |||
| Female | 13 (59.1) | 45 (51.1) | 4163 (47.4) |
| Male | 9 (40.9) | 43 (48.9) | 4618 (52.6) |
| Mean age, years (SD)a | 62.6 (15.7) | 62.2 (11.9) | 62.7 (12.2) |
| Race, n (%) | |||
| Asian | 0 | 0 | 203 (2.3) |
| Black/African American | 2 (9.1) | 4 (4.5) | 816 (9.3) |
| Hispanic/Latino | 0 | 0 | 16 (0.2) |
| White | 18 (81.8) | 80 (90.9) | 5623 (64.0) |
| Other/missing | 2 (9.1) | 4 (4.5) | 2123 (24.2) |
| ECOG PS, n (%) | |||
| 0 | 5 (22.7) | 26 (29.5) | 2146 (24.4) |
| 1 | 9 (40.9) | 28 (31.8) | 2816 (32.1) |
| 2 | 0 | 0 | 822 (9.4) |
| ≥3 | 1 (4.5) | 4 (4.5) | 237 (2.7) |
| Missing | 7 (31.8) | 30 (34.1) | 2760 (31.4) |
| Number of prior lines of treatment, n (%) | |||
| 0 | 3 (13.6) | 12 (13.6) | 1247 (14.2) |
| 1 | 7 (31.8) | 32 (36.4) | 3363 (38.3) |
| 2 | 1 (4.5) | 4 (4.5) | 1120 (12.8) |
| ≥3 | 2 (9.1) | 8 (9.1) | 1208 (13.7) |
| Missing | 9 (40.9) | 32 (36.4) | 1843 (21.0) |
| Year of CGP report, n (%) | |||
| <2019 | 4 (18.2) | 16 (18.2) | 3213 (36.6) |
| 2019 | 2 (9.1) | 8 (9.1) | 1441 (16.4) |
| 2020 | 6 (27.3) | 25 (28.4) | 1381 (15.7) |
| 2021 | 6 (27.3) | 25 (28.4) | 1303 (14.8) |
| 2022 | 3 (13.6) | 10 (11.4) | 1190 (13.6) |
| 2023 | 1 (4.5) | 4 (4.5) | 253 (2.9) |
| Mean follow-up time from CGP report, months (IQR) | 5.0 (16.8) | 10.6 (16.9) | 9.0 (16.1) |
| Mean time from initial diagnosisb to CGP report date, months (IQR) | 2.1 (5.6) | 2.7 (9.8) | 3.9(17.8) |
aPatients with a birth year of 1938 or earlier may have an adjusted birth year in Flatiron datasets due to patient de-identification requirements.
bOf de novo metastatic disease.
ALK, anaplastic lymphoma kinase; CGP, comprehensive genomic profiling; ECOG PS, Eastern Cooperative Oncology Group performance status; IQR, interquartile range; SD, standard deviation; WT, wild type.
| ALK fusion-positive (N = 22) . | ALK-WT (N = 8869) . | ||
|---|---|---|---|
| Matched (N = 88) . | Non-matched (N = 8,781) . | ||
| Sex, n (%) | |||
| Female | 13 (59.1) | 45 (51.1) | 4163 (47.4) |
| Male | 9 (40.9) | 43 (48.9) | 4618 (52.6) |
| Mean age, years (SD)a | 62.6 (15.7) | 62.2 (11.9) | 62.7 (12.2) |
| Race, n (%) | |||
| Asian | 0 | 0 | 203 (2.3) |
| Black/African American | 2 (9.1) | 4 (4.5) | 816 (9.3) |
| Hispanic/Latino | 0 | 0 | 16 (0.2) |
| White | 18 (81.8) | 80 (90.9) | 5623 (64.0) |
| Other/missing | 2 (9.1) | 4 (4.5) | 2123 (24.2) |
| ECOG PS, n (%) | |||
| 0 | 5 (22.7) | 26 (29.5) | 2146 (24.4) |
| 1 | 9 (40.9) | 28 (31.8) | 2816 (32.1) |
| 2 | 0 | 0 | 822 (9.4) |
| ≥3 | 1 (4.5) | 4 (4.5) | 237 (2.7) |
| Missing | 7 (31.8) | 30 (34.1) | 2760 (31.4) |
| Number of prior lines of treatment, n (%) | |||
| 0 | 3 (13.6) | 12 (13.6) | 1247 (14.2) |
| 1 | 7 (31.8) | 32 (36.4) | 3363 (38.3) |
| 2 | 1 (4.5) | 4 (4.5) | 1120 (12.8) |
| ≥3 | 2 (9.1) | 8 (9.1) | 1208 (13.7) |
| Missing | 9 (40.9) | 32 (36.4) | 1843 (21.0) |
| Year of CGP report, n (%) | |||
| <2019 | 4 (18.2) | 16 (18.2) | 3213 (36.6) |
| 2019 | 2 (9.1) | 8 (9.1) | 1441 (16.4) |
| 2020 | 6 (27.3) | 25 (28.4) | 1381 (15.7) |
| 2021 | 6 (27.3) | 25 (28.4) | 1303 (14.8) |
| 2022 | 3 (13.6) | 10 (11.4) | 1190 (13.6) |
| 2023 | 1 (4.5) | 4 (4.5) | 253 (2.9) |
| Mean follow-up time from CGP report, months (IQR) | 5.0 (16.8) | 10.6 (16.9) | 9.0 (16.1) |
| Mean time from initial diagnosisb to CGP report date, months (IQR) | 2.1 (5.6) | 2.7 (9.8) | 3.9(17.8) |
| ALK fusion-positive (N = 22) . | ALK-WT (N = 8869) . | ||
|---|---|---|---|
| Matched (N = 88) . | Non-matched (N = 8,781) . | ||
| Sex, n (%) | |||
| Female | 13 (59.1) | 45 (51.1) | 4163 (47.4) |
| Male | 9 (40.9) | 43 (48.9) | 4618 (52.6) |
| Mean age, years (SD)a | 62.6 (15.7) | 62.2 (11.9) | 62.7 (12.2) |
| Race, n (%) | |||
| Asian | 0 | 0 | 203 (2.3) |
| Black/African American | 2 (9.1) | 4 (4.5) | 816 (9.3) |
| Hispanic/Latino | 0 | 0 | 16 (0.2) |
| White | 18 (81.8) | 80 (90.9) | 5623 (64.0) |
| Other/missing | 2 (9.1) | 4 (4.5) | 2123 (24.2) |
| ECOG PS, n (%) | |||
| 0 | 5 (22.7) | 26 (29.5) | 2146 (24.4) |
| 1 | 9 (40.9) | 28 (31.8) | 2816 (32.1) |
| 2 | 0 | 0 | 822 (9.4) |
| ≥3 | 1 (4.5) | 4 (4.5) | 237 (2.7) |
| Missing | 7 (31.8) | 30 (34.1) | 2760 (31.4) |
| Number of prior lines of treatment, n (%) | |||
| 0 | 3 (13.6) | 12 (13.6) | 1247 (14.2) |
| 1 | 7 (31.8) | 32 (36.4) | 3363 (38.3) |
| 2 | 1 (4.5) | 4 (4.5) | 1120 (12.8) |
| ≥3 | 2 (9.1) | 8 (9.1) | 1208 (13.7) |
| Missing | 9 (40.9) | 32 (36.4) | 1843 (21.0) |
| Year of CGP report, n (%) | |||
| <2019 | 4 (18.2) | 16 (18.2) | 3213 (36.6) |
| 2019 | 2 (9.1) | 8 (9.1) | 1441 (16.4) |
| 2020 | 6 (27.3) | 25 (28.4) | 1381 (15.7) |
| 2021 | 6 (27.3) | 25 (28.4) | 1303 (14.8) |
| 2022 | 3 (13.6) | 10 (11.4) | 1190 (13.6) |
| 2023 | 1 (4.5) | 4 (4.5) | 253 (2.9) |
| Mean follow-up time from CGP report, months (IQR) | 5.0 (16.8) | 10.6 (16.9) | 9.0 (16.1) |
| Mean time from initial diagnosisb to CGP report date, months (IQR) | 2.1 (5.6) | 2.7 (9.8) | 3.9(17.8) |
aPatients with a birth year of 1938 or earlier may have an adjusted birth year in Flatiron datasets due to patient de-identification requirements.
bOf de novo metastatic disease.
ALK, anaplastic lymphoma kinase; CGP, comprehensive genomic profiling; ECOG PS, Eastern Cooperative Oncology Group performance status; IQR, interquartile range; SD, standard deviation; WT, wild type.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
